title: Clinical Response and Adverse Event Profile of Bleomycin Chemotherapy for Canine Multicentric Lymphoma.
abstract: Although canine multicentric lymphoma is initially responsive to multidrug chemotherapy, resistance and relapse create a need for novel chemotherapeutics. Bleomycin is an antitumor antibiotic with a minimal adverse event profile; though commonly used for human non-Hodgkin's lymphoma, its use is poorly characterized in dogs. The purpose of this retrospective case series was to describe the clinical response and adverse event profile of systemic bleomycin for canine multicentric lymphoma (n = 10). A partial response was noted in one dog that died 24 days later due to unrelated disease. Adverse events were infrequent and limited to grade 1 gastrointestinal and grade 1 constitutional toxicity. Although clinical response was minimal, systemic bleomycin was well tolerated when administered at 0.5 U/kg. Additional studies are warranted to determine the influence of administration schedule and dose on the efficacy of bleomycin for veterinary neoplasia.
authors.affiliation: From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.).
authors.forename: Ashley A
authors.initials: AA
authors.lastname: Smith
authors.affiliation: From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.).
authors.forename: Amandine
authors.initials: A
authors.lastname: Lejeune
authors.affiliation: From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.).
authors.forename: Kelvin
authors.initials: K
authors.lastname: Kow
authors.affiliation: From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.).
authors.forename: Rowan J
authors.initials: RJ
authors.lastname: Milner
authors.affiliation: From the Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (A.A.S.); Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.L., C.H.M.S., R.J.M.); and Fitzpatrick Referrals, Godalming, Surrey, United Kingdom (K.K.).
authors.forename: Carlos H M
authors.initials: CH
authors.lastname: Souza
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D012189:Retrospective Studies
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin